Tag Archives: Andreesen Horowitz

Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter

The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments use the CRISPR system as scientists found it in nature, which means it still has limitations when applied to humans, says Benjamin Oakes, CEO of Scribe Therapeutics. Scribe aims to develop gene-editing therapies […]

Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More

Perhaps the most talked-about news at the JP Morgan Healthcare Conference this week was a new startup that launched with $200 million and an ambitious claim that its first drug would be approved within five years, and 10 in total within as many years. Cambridge, MA-based EQRx contends it will be able achieve its goals […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Adaptimmune, Adaptive Phage Therapeutics, Alexis Borisy, Aligos Therapeutics, Allogene Therapeutics, Amarin, amazon, Amunix Pharmaceuticals, Andelyn Biosciences, Andreesen Horowitz, Astellas, AstraZeneca, bayer, BioCryst, Biogen, BioNtech, Biotech, Charles Gayer, clinical trials, CRISPR, Dare Bioscience, deals, Department of Defense, Derek Lowe, Dermira, Disarm Therapeutics, Eli Lilly, Elliot Norry, Emendo Biotherapeutics, epilepsy, EQRx, FDA, Frazier Healthcare Partners, Gene Therapy, Generation Bio, Gilead Sciences, Human Longevity, I-Mab, Idorsia, Incyte, Insilico Medicine, IPO, Ipsen, IT, Jorge Conde, Kyverna Therapeutics, Life Sciences, Lymphoma, Machine Learning, MorphoSys, Nationwide Children’s Hospital, Nektar Therapeutics, NeoGenomics, Neon Therapeutics, Neurocrine Biosciences, opioid, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Schrödinger, Scott Holmes, Software, SpringWorks Therapeutics, startups, Steven Hildemann, Tyra Biosciences | Comments Off

Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More

The brain has stymied many efforts to develop new neuroscience drugs, leading a number of big pharmaceutical companies to pull back on such R&D work. This week, Amgen joined them. Amgen (NASDAQ: AMGN) is ending its research and early development programs in neuroscience, the company announced during a conference call to discuss third-quarter financial results. […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Alkermes, Alphabet, AMAG Pharmaceuticals, Amgen, Andreesen Horowitz, Anne Traas, Assembly Bio, Astellas Pharma, AstraZeneca, Autoimmune Diseases, BeiGene, Bicycle Therapeutics, Biogen, Biotech, Bob Bradway, cancer, Cardiovascular Diseases, clinical trials, Context Therapeutics, Cystic Fibrosis, Cystic Fibrosis Foundation, David Eatwell, David Hung, Dicerna Pharamceuticals, diroximel fumarate, Ed Tucker, Editas Medicine, ER, erenumab, FDA, Fitbit, Genmab, Gilead Sciences, GlaxoSmithKline, google, Hepatitis B, hydroxyprogesterone caproate, I-Mab, Illumina, IMV, Inflammatory Disease, Ironwood Pharmaceuticals, José Octávio Costa Filho, Judith Abrams, Life Sciences, Matthew Sause, Medivation, Migraine, Mirati Therapeutics, Mirum Pharmaceuticals, Multiple Sclerosis, Neuroscience, Nigel Crockett, Nuvation Bio, Oncology, Oyster Point Pharmaceuticals, Pacific Biosciences, Pandion Therapeutics, Passage Bio, Pear Therapeutics, Pfizer, Rafael Pharmaceuticals, RAPT Therapeutics, Richard Morris, Roche, Roche Diagnostics, Scout Bio, Servier, Spark Therapeutics, Tecfidera, Thomas Russo, Tmunity Therapeutics, Type 1 diabetes, University of Pennsylvania, Wisconsin Venture Investors, Zolgensma | Comments Off

Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More

The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers. First, […]

Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged Abiraterone, Allergan, Amgen, Amgen Helix campus, Amicus Therapeutics, Andreesen Horowitz, Arcturus Therapeutics, Biogen, Biotech, blockchain, bortezomib, Bristol-myers Squibb, cancer, Celgene, David Mitchell, deals, dexamethasone, Drugs, duvelisib, Enzalutamide, FDA, fremanezumab, George Church, Gilead Sciences, GlaxoSmithKline, Hans Bishop, Harvard University, HIV, Immunotherapy, Infinity Pharmaceuticals, Intarcia Therapeutics, Ipilimumab, Juno Therapeutics, Life Sciences, Lung Cancer, Migraines, Natalizumab, Nationa Institutes of Health, Nebula Genomics, Nektar Therapeutics, Nivolumab, Opdivo, Pomalidomide, Pomalyst, Pompe disease, Roundups, Sema4, startups, Stroke, Teva Pharmaceutical, Theravance biopharma, Tysabri, ubrogepant, VC, Velcade, Verastem, Xoc Pharmaceuticals, Yervoy | Comments Off

Presence Capital Takes the Temperature of VR/AR at Mid-Year

This week we checked in with Presence Capital, a San Francisco-based venture capital firm that specializes in virtual reality and augmented reality startups. Presence, which made its first investment in July 2015, has now invested in 33 companies, including VR animation studio Baobab; Strivr, a creator of VR training systems; Meta, the developer of a […]

Posted in National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged AltspaceVR, Amitt Mahajan, Andreesen Horowitz, apple, Apple ARKit, Applied VR, Artificial Intelligence (AI), Augmented Reality, Baobab, Betaworks, deals, Devices, Entrepreneurship, facebook, Financing, funding, Glass Enterprise Edition, google, Google Glass, Hardware, Holograms, HTC Vive, Internet, Investor, IT, Linden Lab, Magic Leap, meta, Microsoft, Microsoft’s Hololens, Mobile, Oculus Rift, Playstation VR, Presence Capital, Rothenberg Ventures, Samsung GearVR, SanFranciscoVC, Sequoia Capital, Snapchat, Software, sony, startups, Strivr, SVAngel, VC, Venture Capital, Virtual Reality (VR), Voice Interactivity, WalMart, Web, Zynga | Comments Off

San Antonio’s Geekdom Fund Adds to Investments With $20M Second Fund

San Antonio—The Texas IT-focused venture capital firm Geekdom Fund has closed a $20 million fund, which it started raising last year. The San Antonio venture firm was founded in 2014 by Michael Girdley, Don Douglas, Mike Troy, and Cole Wollak, and closed its first fund at $3.4 million in 2015. Geekdom Fund has always invested […]

Posted in Boston blog main, National blog main, San Francisco blog main, Texas, Texas blog main, Texas top stories | Tagged acquire, acquired, Acquisition, Andreesen Horowitz, Athenahealth, Chowbiotics, cisco, Cole Wollak, Dauber, Don Douglas, Geekdom, Geekdom Fund, Geekdom Fund II, investing, investmetn, IT startups, Medspoke, Merge VR, Michael Girdley, Mike Troy, Patient IO, San Antonio, San Antonio VC, San Antonio venture capital, Sea Machines, SeatSmart, Tech, Technology, Tenfold, TexasVC, TicketIQ, VC, Venture Capital, WorkLife | Comments Off

Senate Confirms Price for HHS, But Stock Deals Still Raise Questions

The Senate confirmed Tom Price as Secretary of the U.S. Department of Health and Human Services early Friday morning by a 52-47 vote that, as expected, fell largely on party lines. Price is an orthopedic surgeon by training who has been a member of Georgia’s congressional delegation since 2004. He will now oversee a department that […]

Start Houston, Gigster Partner to Match Developers With Startups

Start Houston co-founder and tech entrepreneur Apurva Sanghavi found himself in a predicament familiar to many entrepreneurs: an incomplete project was stalled because of a lack of developers. Almost on a whim, he turned to Gigster, a San Francisco-based startup that connects freelance developers to entrepreneurs like Sanghavi. Hiring Gigster gave him the developer talent […]

Posted in National blog main, National top stories, San Francisco blog main, Texas, Texas blog main, Texas top stories | Tagged Accelerator, Andreesen Horowitz, Apurva Sanghavi, co-working, Curiosoft, Dallas, Demo Day, developers, Engineers, entrepreneurs, funding, Gaurav Khandelwal, Gigster, Houston, investment, IT, Mafia Wars, people, programmers, Roger Dickey, San Francisco, Software, Start Houston, startups, talent, Venture Capital, Workforce, Zynga | Comments Off

Techstars Alum DigitalOcean to Double Staff, Office Space with $83M

Next week, the team at DigitalOcean will move into a 30,000-square-foot office, in the same building but twice the size of its current digs, as it ramps up with more funding in hand. The New York-based company hosts cloud infrastructure, largely used by developers to build websites and apps. Along with the extra elbow room, […]

Posted in Boulder/Denver blog main, National blog main, New York, New York blog main, New York top stories | Tagged Access Industries, Andreesen Horowitz, Atlantic.Net, BlueMix, cloud computing, cloud hosting, Cloud-Based Services, deals, DigitalOcean, GitHub, IBM, IT, Mitch Wainer, oracle, startups, TechStars | Comments Off

VC Funding Slows as Big Funds Crowd into Late-Stage Venture Deals

Following a December surge, when U.S. venture firms invested $7.2 billion in 342 deals nationwide, VC activity reset at a lower pace during the first quarter of 2015, according to data being released today by CB Insights. The New York venture capital tracker says VCs invested $11.3 billion in 805 startups over the three months […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Accela, acquisitions, Algal Scientific, Allergen Research Corp., Andreesen Horowitz, Biotech, CB Insights, cleantech, Devices, Entrepreneurship, Financing, funding, healthcare, Hedge Funds, innovation, Innovation Economy, Internet, IPOs, IT, Life Sciences, Lyft, Lynda, M&As, Mergers & Acquisitions, Mobile, Mutual Funds, Pinterest, Private Equity Funds, Sakti3, Simplivity, Snapchat, Social Finance, Software, startups, Tech, Telecom, Uber, VC, Venture Capital, Venture Capital Surveys, wireless | Comments Off← Older posts